About Summit:

Ivonescimab, known as SMT112, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity when in the presence of both PD-1 and VEGF.

Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), with three active Phase III trials:

• HARMONi is a Phase III clinical trial which intends to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib).

• HARMONi-3 is a Phase III clinical trial which is designed to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

• HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was approved for marketing authorization in China in May 2024. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.

Overview of Role:

The Senior Vice President (SVP), US Marketing will lead the development and execution of the U.S. marketing strategy for the company’s commercial asset, ivonescimab. As the top U.S. commercial leader for this brand, the SVP will be accountable for all aspects of U.S. marketing, including launch preparation, brand positioning, promotional strategy, digital/omnichannel marketing, HCP and patient engagement, and performance optimization. This is a highly visible and mission-critical role, with a mandate to build a best-in-class brand presence in the U.S. market, shape the organization’s commercial culture, and deliver strong business results.

Role and Responsibilities:

• Develop and lead the comprehensive U.S. marketing strategy for ivonescimab ensuring differentiation, strong market uptake, and sustained growth
• Build the U.S. brand plan, including positioning, value proposition, messaging, and go-to-market strategy across channels and stakeholders
• Own and drive U.S. launch readiness, including development of HCP and patient campaigns, sales force enablement, and market shaping activities.
• Establish KPIs and performance metrics to guide execution and optimize impact pre- and post-launch
• Builds and develops a high-performing, top-tier marketing team to execute strategic initiatives
• Foster a culture of agility, accountability, innovation, and collaboration.
• Collaborates cross-functionally to ensure alignment and seamless execution of strategic and tactical plans
• Oversees investment planning and budget management to maximize brand growth and return on investment
• Translates insights from market research, key opinion leader (KOL) engagement, and external stakeholders into actionable business opportunities
• Aligns the organization around brand priorities and key growth opportunities, while proactively planning for potential competitive challenges
• Owns and validates the brand’s revenue forecast, incorporating risk assessments and opportunity analyses
• Drives innovation and adapts strategies to succeed in today’s dynamic launch and commercialization landscape
• All other duties as assigned

Experience, Education and Specialized Knowledge and Skills:

• Advanced degree in Business, Marketing, Life Sciences, or a related field (MBA, MS, or PhD preferred)
• Minimum of 15+ years of progressive experience in pharmaceutical marketing, with at least 7+ years in senior leadership roles
• Demonstrated success in leading U.S. launch and/or commercialization of a specialty or first-in-class therapy
• Must have recent launch experience; a large-scale brand with multiple competitors is a plus
• Must have experience and understanding of U.S. market including key drivers and barriers; global experience is a plus
• Proven track record of successfully commercializing Oncology pharmaceutical products, including immuno-oncology (I-O) experiences
• Broad background across solid tumors is required; oncology lung experience is a plus
• Sales experience, in addition to marketing, is a plus
• Need to demonstrate understanding of innovative approaches to launches including digital marketing, SEO optimization, use of ML and AI for no see customers and just in time patients etc.
• Keen grasp of the U.S. Oncology customer landscape, working with access and medical to ensure proper access and use of product
• Understanding of compliance standards and acting within those standards
• Demonstrated leadership, teamwork & team building and cross-functional collaboration
• Must have drive, energy, persuasion, imagination, adaptability and versatility
• Exceptional leadership, communication, and influencing skills
• Analytical mindset with the ability to translate insights into impactful strategy

The pay range for this role is $400,000-$430,000 annually. Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.